
DRTS Stock Forecast & Price Target
DRTS Analyst Ratings
Bulls say
Alpha Tau Medical is currently in a favorable position with its strategic U.S. partnership with Tolmar, a strong runway of cash through 2027, and upcoming data from its U.S. pancreatic cancer pilot study and ongoing clinical trials. The company's Alpha DaRT technology shows promising results and has the potential to be a compelling localized radiation therapy for several types of solid tumors. However, risks such as failure in clinical trials, regulatory approval, and achieving commercial success should be closely monitored. Overall, Alpha Tau Medical has a strong potential for growth and is a Buy with a 12-month price target of $15 per share.
Bears say
Alpha Tau Medical is a clinical-stage oncology therapeutics company, but with a lack of commercial success potential due to market size, penetration rate, and competition, as well as a potential dilution risk. Additionally, the failure of Alpha DaRT to secure regulatory approval in the U.S. and potential failure in clinical trials are major risks. Return on Investment (ROI) and revenue generation are also uncertain, making Alpha Tau Medical's stock a high-risk investment with a negative outlook.
This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.
DRTS Analyst Forecast & Price Prediction
Start investing in DRTS
Order type
Buy in
Order amount
Est. shares
0 shares